BillionToOne (BLLN) vs Concentra Group Parent (CON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Concentra Group Parent (CON) has outperformed BillionToOne (BLLN) over the past year, gaining 106.8% versus a loss of 18.3%. Concentra Group Parent is the larger company by market cap ($5.26 billion vs $4.30 billion), about 1.2 times the size, while BillionToOne is growing revenue faster (+100.0% vs +13.9%). On valuation, Concentra Group Parent trades at a lower forward P/E (22.0x vs 57.3x for BillionToOne).
Concentra Group Parent pays a dividend yielding 0.60%, while BillionToOne does not currently pay one. Concentra Group Parent converts more of its revenue into profit, with a net margin of 7.7% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | CON |
|---|---|---|
| Share price | $89.92 | $41.84 |
| Market cap | $4.30B | $5.26B |
| 1-day change | -0.31% | +0.94% |
| YTD return | +9.87% | +112.60% |
| 1-year return | -18.25% | +106.82% |
| P/E ratio (TTM) | 97.74 | 24.76 |
| Forward P/E | 57.27 | 21.99 |
| EPS (TTM) | $0.92 | $1.69 |
| Dividend yield | 0.00% | 0.60% |
| Annual dividend | $0.00 | $0.25 |
| Revenue (latest FY) | $305.11M | $2.16B |
| Revenue growth (YoY) | +99.97% | +13.85% |
| Net income (latest FY) | $7.45M | $166.41M |
| Gross margin | 68.32% | 28.34% |
| Operating margin | 5.25% | 15.44% |
| Net margin | 2.44% | 7.69% |
| 52-week high | $150.44 | $44.22 |
| 52-week low | $61.96 | $19.05 |
| Distance from 52-week high | -40.23% | -5.38% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +42.67% | +11.62% |
| Average volume | 639.36K | 1.05M |
| Shares outstanding | 43.27M | 125.72M |
| Employees | 713 | 9,967 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CON has outperformed BLLN by 125.1 percentage points over the past year.
- BillionToOne trades at a higher earnings multiple (97.7x vs 24.8x trailing P/E).
- Concentra Group Parent is more profitable, keeping 7.7 cents of every revenue dollar as net income versus 2.4 cents for BillionToOne.
- BillionToOne grew revenue faster in its latest fiscal year (+99.97% vs +13.85%).
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About Concentra Group Parent
CON stock →Concentra Group Holdings Parent, Inc. provides occupational health services in the United States.
Health Care · Medical Specialities · 9,967 employees
BLLN vs CON FAQ
Which is bigger, BillionToOne or Concentra Group Parent?
Concentra Group Parent (CON) is larger, with a market capitalization of $5.26B compared with $4.30B for BillionToOne (BLLN).
Which stock has performed better over the past year, BLLN or CON?
CON returned +106.82% over the past 12 months, compared with -18.25% for BLLN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BLLN or CON?
CON has the lower trailing P/E at 24.8, versus 97.7 for BLLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BillionToOne or Concentra Group Parent?
Concentra Group Parent pays a dividend yielding 0.60%, while BillionToOne does not currently pay a regular dividend.
Are BillionToOne and Concentra Group Parent in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.